Worth reading
32Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Deterioration
Direction inferred from the company’s description.Scale
22864
¥ thousandWording
Definitive
How definitive the wording is.Recognition of non-operating expenses (interest expense)
Subject Entity
Kidswell Bio Corporation (filing company)
OccurrenceRecorded during the period from 1 April 2026 to 30 June 2026 (the cumulative consolidated first-quarter period of the fiscal year ending March 2027). No single event date is specified.
This disclosure08/13/2026
Cause
Expenses and other costs related to bank borrowings
Amount of Impact on Business Performance
¥22.864 million (non-operating expenses; interest expense)
Accounting period in which recognized
Cumulative consolidated period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026)
Impact on Earnings Forecast
See the “Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)” disclosed today.
Outlook
The company advises readers to refer to the First-Quarter Financial Results disclosed today for the impact on results.
| Item | Details |
|---|---|
| Event name | Recognition of non-operating expenses (interest expense) |
| Date of occurrence | Recorded during the period from 1 April 2026 to 30 June 2026 (the cumulative consolidated first-quarter period of the fiscal year ending March 2027). No single event date is specified. |
| Subject Entity | Kidswell Bio Corporation (filing company) |
| Cause | Expenses and other costs related to bank borrowings |
| Amount of Impact on Business Performance | ¥22.864 million (non-operating expenses; interest expense) |
| Accounting period in which recognized | Cumulative consolidated period for the first quarter of the fiscal year ending March 2027 (1 April 2026 to 30 June 2026) |
| Impact on Earnings Forecast | See the “Summary of Financial Results for the First Quarter of the Fiscal Year Ending March 2027 [Japanese GAAP] (Consolidated)” disclosed today. |
| Outlook | The company advises readers to refer to the First-Quarter Financial Results disclosed today for the impact on results. |
Items this document does not state (17)
Date recognized / date notice receivedTarget Locations / ProductsType of litigation or proceedingCourt or authorityPlaintiffDefendantDate of filing / date of actionClaim amount / surcharge amountAmount of receivables at risk of non-collection or delayed collectionSuspended operationsScheduled resumption dateInvestigation structureMeasures to prevent recurrenceDirectors' and officers' liabilityVoting rights ownership percentage before the changeVoting rights ownership percentage after the changePlanned follow-up disclosure
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Expenses and other costs related to bank borrowings
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.